Therapeutic-grade biologics are expensive, challenging to source and only available in large quantities, making studies using these antibodies cost prohibitive.
To overcome these restrictions, research-grade biosimilar antibodies are produced by recombinant technology using the variable region sequences of therapeutic antibodies, resulting in the same specificities as approved biologics.
Leinco Technologies‘ recombinant biosimilar antibodies are ideal research tools as they are fast, inexpensive, manufactured in an animal-free facility and formulated in sterile PBS buffer, free of additives or preservatives.
For a limited time only, you can get 10% off Leinco’s biosimilar antibodies, allowing your research budget to go even further!
Offer Details
Get 10% off Leinco Technologies’ Biosimilar Antibodies.
You can claim this offer by mentioning promo code ‘CALQ2PROMO‘ when contacting us.
This offer is valid from 4th March 2025 until 31st April 2025.
About Leinco’s Biosimilars
Biosimilar recombinant molecules target specific proteins in the cell to treat cancer, auto-immune disorders, and many more disease areas. Due to their high efficacy, demand for more biosimilars to treat these and other conditions is rising.
Increasing need for biotherapeutics relies on building a solid foundation in discovery, translational research and pre-clinical studies. These studies rely on the availability of high-quality, research-grade biosimilars to support the cost-effective generation of reliable data. To meet this need, Leinco Technologies provides a range of research-grade biosimilars, including Fc-muted forms to avoid unwanted effector functions.
These antibodies are produced by recombinant technology with advantages of:
- economical research-grade for preclinical studies
- lot-to-lot consistency
These antibodies have the same specificities as the approved biologics, with high purity backed by extensive QC.
Leinco’s Biosimilar Specifications
- Purity > 95% by SDS-PAGE and ≥ 98% monomer by analytical SEC
- Endotoxin ≤ 0.5 EU/mg as determined by the LAL method
- Manufactured in an animal-free facility using protein-free, animal-origin-free cell culture media
- Ultra-low levels of leached protein A
- Sterile filtered and formulated in Leinco’s in vivo grade PBS pH 7.2 containing no K or Ca, additives, preservatives, or carrier proteins
- Many applications – including FC, ELISA, IHC, FA, PK, potency assays and IVD
- Pathogen tested (IMPACT1)
About Leinco Technologies
Leinco Technologies is a biotechnology company founded in 1992 as a specialty manufacturer of early discovery research products including antibodies, recombinant proteins, ELISA kits, second-step reagents and other life sciences products. They offer an extensive line of recombinant biosimilar antibodies at the in vivo functional purity levels you have come to know and trust from Leinco Technologies.
Shortly thereafter, they also established themselves as a premier provider of custom Research & Development and manufacturing services, focusing on monoclonal antibodies and recombinant proteins.
Their innovative products and services are used to augment the early discovery process in life science research, diagnostics and groundbreaking development of protein therapeutics.
Caltag Medsystems is the distributor of Leinco Technologies’ products in the UK and Ireland.